AcelRx Pharmaceuticals, Inc. — Q1 2012 Form 10-Q
Entity note: The supplied filing is for AcelRx Pharmaceuticals, Inc., not TALPHERA, INC. It covers the quarter ended March 31, 2012; financial amounts below are in U.S. dollars unless stated otherwise.
Business context and reporting period
AcelRx was a development-stage specialty pharmaceutical company developing treatments for acute and breakthrough pain. It had no product sales; its only reported revenue was research-grant reimbursement. The filing is unaudited and compares the three months ended March 31, 2012 with the same period in 2011.
ARX-01, a sublingual sufentanil delivery system for post-operative pain, was the lead program. The first of three planned Phase 3 trials began in March 2012. The second began in April 2012, after quarter-end. ARX-04 was being developed with support from a U.S. Army research grant; ARX-02 and ARX-03 were earlier-stage programs.
Key financial metrics
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Grant revenue | $0.329 million | None |
| Research and development expense | $4.771 million | $1.946 million |
| General and administrative expense | $2.104 million | $1.589 million |
| Total operating expenses | $6.875 million | $3.535 million |
| Net loss | $7.065 million | $3.204 million |
| Net loss per share, basic and diluted | $0.36 | $0.30 |
| Net cash used in operating activities | $7.761 million | $1.375 million |
At March 31, 2012, cash and cash equivalents were $4.469 million and short-term investments were $23.102 million, totaling $27.571 million. Current assets were $31.070 million and current liabilities $8.949 million, yielding working capital of approximately $22.1 million. Total assets were $33.990 million; total liabilities were $22.959 million.
Debt was approximately $19 million net of discounts on the balance sheet. The Hercules loan had $20 million in original borrowings, an 8.5% interest rate, interest-only payments through June 30, 2012, and scheduled maturity on December 1, 2014. The debt is secured by substantially all assets other than intellectual property. No operating margin was reported; the company was loss-making and had no product revenue.
Changes versus the prior comparable period
- R&D expense rose $2.825 million, or 145%, mainly due to ARX-01 Phase 3 development, with additional ARX-04 and personnel costs.
- G&A expense increased $0.515 million, or 32%, primarily from patent prosecution, market research, and personnel costs.
- Net loss increased $3.861 million. Lower interest expense ($0.594 million versus $1.359 million) partly offset higher operating expenses. Q1 2011 also included substantial non-recurring gains related to warrants and a convertible-note call option, contributing to the difference in other income.
- Operating cash use increased to $7.761 million from $1.375 million. Cash and investments fell approximately $8.2 million from year-end 2011.
Outlook, risks, and notable items
- Management said existing cash, cash equivalents, investments, and the Army grant were expected to fund currently planned operations into the first quarter of 2013. It also said substantial additional capital would be needed for future operations; additional financing or partnerships might not be available on acceptable terms.
- Management expected R&D spending to increase as ARX-01 advanced through Phase 3. It expected top-line results from the three ARX-01 trials in late 2012 or early 2013 and intended, subject to funding, to submit an NDA later in 2013. These were forward-looking expectations, not guarantees.
- The $5.6 million USAMRMC award reimbursed eligible ARX-04 development costs. Its research period ran through August 31, 2012, and further funding or extension was not assured; the planned Phase 2 study depended on approval of the proposed protocol.
- Key risks include clinical-trial delays or failure, FDA review of a drug-device combination and opioid-related restrictions, dependence on third-party manufacturing and limited supply sources, DEA controls on sufentanil, and the need for additional capital. The company reported no litigation it believed would materially adversely affect its financial condition or results.
- Management concluded disclosure controls were effective at the reasonable-assurance level and reported no significant changes in internal control over financial reporting during the quarter. The filing reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm that this AcelRx filing is the intended company filing, given the TALPHERA, INC. request metadata.
- Track ARX-01 Phase 3 enrollment, completion, safety and efficacy results, and any changes to the expected NDA timing.
- Reconcile the reported debt figures and review Hercules repayment terms, collateral, and the shift from interest-only to principal-and-interest payments.
- Assess cash consumption against the stated first-quarter 2013 runway, including clinical-trial spending and the availability of additional financing.
- Verify USAMRMC grant reimbursement, approval and funding status for ARX-04, and the company’s manufacturing and supply readiness.